scholarly journals Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies

2021 ◽  
Vol 14 (1) ◽  
pp. 676-680
Author(s):  
Quentin Perrier ◽  
Johan Noble ◽  
Steven Grangé ◽  
Pierrick Bedouch ◽  
Rachel Tetaz ◽  
...  
Keyword(s):  
Blood Cell ◽  
Hemolytic Uremic Syndrome ◽  
Red Blood Cell ◽  
Transfusion Requirement ◽  
Breast Adenocarcinoma ◽  
Slight Reduction ◽  
Dramatic Reduction ◽  
Line Therapy ◽  
Good Clinical Condition ◽  
Uremic Syndrome

Thrombotic microangiopathy (TMA) is most of the time caused by thrombotic thrombocytopenic purpura or hemolytic uremic syndrome. A 60-year-old female was diagnosed in 2014 with mammary breast adenocarcinoma treated by several-line therapy: mastectomy, docetaxel, cyclophosphamide, radiotherapy, doxorubicine, and capecitabine. By mid-November, the patient was admitted to the hospital with regenerative, mechanical, and hemolytic anemia, schistocytes at 3%, and thrombopenia (99 G/L), associated with high blood transfusion requirement. After 9 sessions of plasmapheresis, there was no significant improvement in the biological parameters, nor after 2 cycles of paclitaxel. The patient was then treated with eculizumab during 4 weeks, with a slight reduction in blood requirement, and simultaneously with palbociclib. Since being treated with palpociclib, she had a great reduction in blood requirement and a good clinical condition. To conclude, we reported an initial moderate improvement of paraneoplasm-related TMA syndrome under eculizumab therapy with a slight reduction in red blood cell requirement; however, palbociclib therapy achieved a very good response with a dramatic reduction in red blood cell requirement.

Red blood cell Thomsen-Friedenreich antigen expression and galectin-3 plasma concentrations inStreptococcus pneumoniae-associated hemolytic uremic syndrome and hemolytic anemia

Transfusion ◽  
2014 ◽  
Vol 55 (6pt2) ◽  
pp. 1563-1571 ◽  
Author(s):  
Nicolas Burin des Roziers ◽  
Philippe Chadebech ◽  
Gwellaouen Bodivit ◽  
Emmanuelle Guinchard ◽  
Arnaud Bruneel ◽  
...  
Keyword(s):  
Blood Cell ◽  
Hemolytic Uremic Syndrome ◽  
Hemolytic Anemia ◽  
Red Blood Cell ◽  
Plasma Concentrations ◽  
Antigen Expression ◽  
Galectin 3 ◽  
Uremic Syndrome

Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome—a randomized prospective pilot trial

2009 ◽  
Vol 24 (5) ◽  
pp. 1061-1064 ◽  
Author(s):  
Lars Pape ◽  
Thurid Ahlenstiel ◽  
Martin Kreuzer ◽  
Jens Drube ◽  
Kerstin Froede ◽  
...  
Keyword(s):  
Blood Cell ◽  
Hemolytic Uremic Syndrome ◽  
Red Blood Cell ◽  
Pilot Trial ◽  
Red Blood Cell Transfusion ◽  
Uremic Syndrome

Complement deposition on red blood cells and red blood cell-derived microparticles during hemolytic uremic syndrome

2013 ◽  
Vol 56 (3) ◽  
pp. 284-285
Author(s):  
I. Arvidsson ◽  
A.-L. Ståhl ◽  
M. Manea Hedström ◽  
A.-C. Kristoffersson ◽  
J. Westman ◽  
...  
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Hemolytic Uremic Syndrome ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Uremic Syndrome ◽  
Complement Deposition

scholarly journals Shiga Toxin–Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cell–Derived Microvesicles in Hemolytic Uremic Syndrome

2015 ◽  
Vol 194 (5) ◽  
pp. 2309-2318 ◽  
Author(s):  
Ida Arvidsson ◽  
Anne-lie Ståhl ◽  
Minola Manea Hedström ◽  
Ann-Charlotte Kristoffersson ◽  
Christian Rylander ◽  
...  
Keyword(s):  
Blood Cell ◽  
Hemolytic Uremic Syndrome ◽  
Red Blood Cell ◽  
Shiga Toxin ◽  
Uremic Syndrome

Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome

2015 ◽  
Vol 30 (12) ◽  
pp. 2115-2119 ◽  
Author(s):  
Carlos J. Cobeñas ◽  
Paula S. Bresso ◽  
Laura L. Lombardi ◽  
Oscar R. Amoreo ◽  
Javier D. Ruscasso ◽  
...  
Keyword(s):  
Blood Cell ◽  
Renal Disease ◽  
Hemolytic Uremic Syndrome ◽  
Red Blood Cell ◽  
Acute Stage ◽  
Red Blood Cell Transfusion ◽  
Transfusion Requirements ◽  
Uremic Syndrome

Transfusion Requirements in Nonmyeloablative Allogeneic Stem Cell Transplantation for Hematologic Malignancies.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4178-4178
Author(s):  
Jason W. Brown ◽  
Darrell J. Triulzi
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Platelet Transfusion ◽  
Transfusion Requirement ◽  
Hematologic Malignancies ◽  
Packed Red Blood Cells ◽  
Transfusion Requirements ◽  
Cell Transplants

Abstract Nonmyeloablative allogeneic stem cell transplants (NM-ASCT) are increasingly being utilized to treat hematologic malignancies in settings where high dose, fully ablative regimens would not be tolerated. We identified 10 male and 13 female patients (n=23) ranging in age from 19 to 63 years old (mean=48) representing all patients whom had undergone NM-ASCT in the last five years. NM-ASCT were performed for acute myelogenous leukemia (n=7), non-Hodgkin’s lymphoma (n=6), Hodgkin’s disease (n=4), multiple myeloma (n=3), myelodysplastic syndrome (n=2), and acute lymphoblastic leukemia (n=1). The majority of patients had undergone at least one previous stem cell transplant (n=16). The mean number of stem cells infused per kilogram at time of transplant was 4.72 X 106 ±1.97 X 106 stem cells and mean time to engraftment was 15.8 ±5.15 days (3 consecutive days with ANC >500). All of the subjects required both platelet and red cell transfusion during the period of analysis. Mean transfusion requirements in the 7 days prior to transplantation were 3.1 ±5.9 units of platelets and 1.2 ±1.5 units of packed red blood cells. Mean platelet transfusion requirements 90 days post transplant were 73.7 ±79.7 units and mean red cell requirements 11.6 ±8.3 units. Total mean transfusion requirements during the time period analyzed were 76.9 ±82.2 units of platelets and 12.8 ±8.9 units of packed red blood cells. There was no significant correlation between the number of stem cells infused per kilogram on day of transplant, the number of previous transplants, or the time to engraftment with red blood cell or platelet transfusion requirements. Our data illustrate a higher proportion of patients requiring platelet transfusions (100% vs. 23%) and red blood cell transfusions (100% vs. 63%) as well as a higher platelet transfusion requirement (median 48 vs. 0 units) and packed red blood cell transfusion requirement (median 11 vs. 2 units) than other authors have reported in a 60 day period in HLA-matched sibling NM-ASCT [Weissinger et al. Blood 98(13):3584-8, 2001]. As is illustrated by the percentage of patients undergoing previous fully ablative stem cell transplants, our patients represent a heavily pretreated population and this may account for the higher transfusion requirements seen in this analysis. Although patients undergoing NM-ASCT receive reduced intensity therapy, in our analysis their transfusion requirements remain substantial.

scholarly journals Erythrocyte membrane proteins reactive with IgG (warm-reacting) anti- red blood cell autoantibodies: II. Antibodies coprecipitating band 3 and glycophorin A

Blood ◽  
1994 ◽  
Vol 84 (2) ◽  
pp. 650-656 ◽  
Author(s):  
JP Leddy ◽  
SL Wilkinson ◽  
GE Kissel ◽  
ST Passador ◽  
JL Falany ◽  
...  
Keyword(s):  
Membrane Proteins ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Band 3 ◽  
Slight Reduction ◽  
Glycophorin A ◽  
Immunochemical Study ◽  
Rbc Membrane ◽  
Indirect Antiglobulin Test ◽  
Serologic Evidence

Abstract In our initial immunochemical study of the red blood cell (RBC) membrane proteins targeted in 20 cases of warm-antibody autoimmune hemolytic anemia (AHA), RBC eluates of 6 patients mediated immunoprecipitation (IP) of both band 3 and glycophorin A (GPA). This dual IP pattern had previously been observed with murine monoclonal antibodies (MoAbs) against the high frequency blood group antigen, Wrb (Wright), suggesting that the Wrb epitope may depend on a band 3-GPA interaction. Earlier, anti-Wrb had been identified serologically as a prominent non-Rh specificity of AHA autoantibodies. In the present study, 6 autoantibody eluates immunoprecipitating band 3 and GPA from common Wr(b+) RBCs were retested, in parallel with murine anti-Wrb MoAbs, against very rare Wr(a+b-)En(a+)RBCs. One patient's autoantibodies were unreactive with the Wr(b-) RBCs by either IP or indirect antiglobulin test (IAT) and were judged to have “pure” anti- Wrb specificity. Two other patients' autoantibodies displayed both IP and serologic evidence for anti-Wrb as a major component in combination with one or more additional specificities. However, among 3 other patients whose autoantibodies coprecipitated band 3 and GPA, there was no reduction in IP or IAT reactivity with Wr(b-) RBCs in 2 and only slight reduction in the third. We conclude (1) that human anti-Wrb autoantibodies, like their murine monoclonal counterparts, coprecipitate band 3 and GPA from human RBCs; but (2) that not all antibodies with this IP behavior have anti-Wrb serologic specificity, as defined by this donor's Wr(b-) RBCs. The possibility of an additional (non-Wrb) RBC epitope dependent on a band 3-GPA interaction is raised.

scholarly journals First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis

2014 ◽  
Vol 40 (1) ◽  
Author(s):  
Nóra Szarvas ◽  
Ágnes Szilágyi ◽  
Velibor Tasic ◽  
Valbona Nushi-Stavileci ◽  
Aspazija Sofijanova ◽  
...  
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Poor Prognosis ◽  
Atypical Hemolytic Uremic Syndrome ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Uremic Syndrome
Sign in / Sign up

Export Citation Format

Share Document